Survivin is an oncogenic
protein that is highly expressed in
breast cancer and has a dual function that is dependent on its subcellular localization. In the cytosol,
survivin blocks programmed cell death by inactivating
caspase proteins; however, in the nucleus it facilitates cell division by regulating chromosomal movement and cytokinesis. In prior work, we showed that
survivin is acetylated by
CREB-binding protein (CBP), which restricts its localization to the nuclear compartment and thereby inhibits its anti-apoptotic function. Here, we identify
histone deacetylase 6 (HDAC6) as responsible for abrogating CBP-mediated
survivin acetylation in the
estrogen receptor (ER)-positive
breast cancer cell line, MCF-7. HDAC6 directly binds
survivin, an interaction that is enhanced by CBP. In quiescent
breast cancer cells in culture and in malignant tissue sections from ER+
breast tumors, HDAC6 localizes to a perinuclear region of the cell, undergoing transport to the nucleus following CBP activation where it then deacetylates
survivin. Genetically modified mouse embryonic fibroblasts that lack mhdac6 localize
survivin predominantly to the nuclear compartment, whereas wild-type mouse embryonic fibroblasts localize
survivin to distinct cytoplasmic structures. Together, these data imply that HDAC6 deacetylates
survivin to regulate its nuclear export, a feature that may provide a novel target for patients with ER+
breast cancer.